Itraconazole IR Pellets 22.5% W/W & 40% W/W Pellets

What are Itraconazole IR Pellets 22.5% W/W & 40% W/W?

Itraconazole IR Pellets 22.5% W/W and 40% W/W are pharmaceutical formulation intermediates containing itraconazole at two stated drug loadings. They are intended for further pharmaceutical processing, subject to confirmation of their composition and technical specifications. The release characteristics, excipient profile, and suitability for a particular finished dosage form should be established from supplier documentation and appropriate testing.

Uses / Applications

Itraconazole is an antifungal active ingredient used in finished medicines for certain fungal infections, depending on the indication and approved product information.

Potential pharmaceutical applications of itraconazole-containing intermediates include:

• Development of oral antifungal formulations.

• Further processing into suitable finished dosage forms.

• Formulation research and pharmaceutical manufacturing, subject to technical validation.

Important: These are general applications of the active ingredient. The pellets are formulation intermediates and should not be assumed suitable for direct patient administration.

5. Benefits

Potential formulation-related considerations include:

• Two stated drug loadings: Available in 22.5% w/w and 40% w/w grades.

• Defined active ingredient: Itraconazole is the specified active ingredient.

• Formulation development: May be evaluated for suitable downstream manufacturing applications.

• Sourcing support: Kelar Pharmachem India supports pharmaceutical sourcing and export requirements.

Actual suitability depends on the composition, release performance, stability, and validated specifications of each grade.

6. Side Effects

Itraconazole-containing finished medicines may cause side effects, including:

• Nausea or abdominal discomfort.

• Diarrhea or vomiting.

• Headache.

• Elevated liver enzymes or liver injury.

• Swelling or other signs of fluid retention in some patients.

Itraconazole can also cause serious drug interactions and may be unsuitable for patients with certain heart conditions. These are general active-ingredient safety considerations, not product-specific clinical claims about the pellet intermediate.

7. How Does It Work?

Itraconazole is a triazole antifungal agent. It inhibits a fungal enzyme involved in the production of ergosterol, an important component of fungal cell membranes. Disruption of ergosterol production interferes with fungal cell membrane formation and function.

The performance of a finished medicine depends on its formulation, absorption, quality, and appropriate clinical use. The actual release and dissolution characteristics of these pellets must be confirmed separately.

8. Dosage Guidelines / Processing Instructions

• Available stated drug loadings: 22.5% w/w and 40% w/w.

• Confirm the composition and release profile of each grade against the supplier’s technical documentation.

• Determine quantities using verified drug-loading data and validated formulation calculations.

• Assess compatibility with excipients and other formulation ingredients.

• Evaluate relevant quality attributes, including assay, content uniformity, dissolution, and stability.

Note: These instructions relate to pharmaceutical processing, not patient dosing. The pellets should not be used directly as a finished medicine unless specifically established and authorized for that purpose.

9. When Not to Use

For manufacturing purposes, do not use the material if its identity, quality, specification, or storage history cannot be verified.

For finished itraconazole medicines, use may be contraindicated or restricted in circumstances such as:

• Known hypersensitivity to itraconazole or related azole antifungals.

• Certain heart conditions, particularly ventricular dysfunction or congestive heart failure, depending on the indication and product labeling.

• Concomitant use of medicines that have serious interactions with itraconazole.

• Other contraindications listed in the approved product information.

A qualified healthcare professional should assess clinical suitability.

10. Drug / Product Interactions

Itraconazole has a substantial interaction profile. Important considerations include:

• CYP3A4 substrates: Itraconazole can increase concentrations of certain medicines metabolized by this enzyme, potentially causing serious adverse effects.

• Acid-reducing medicines: Some medicines that reduce stomach acidity can affect the absorption of certain itraconazole oral formulations.

• Other antifungals or interacting medicines: Compatibility and clinical use require specific evaluation.

• Formulation ingredients: Physical and chemical compatibility must be assessed during product development.

The relevance of an interaction depends on the final formulation, co-administered medicine, and approved product information.

11. Safety Advice

• Follow applicable material safety documentation and site-specific handling procedures.

• Use appropriate personal protective equipment based on the risk assessment.

• Minimize dust generation during sampling, weighing, and processing.

• Verify the identity, assay, impurities, and other applicable quality attributes before use.

• Request the relevant technical data sheet and certificate of analysis when available.

12. General Instructions

• Confirm whether the 22.5% w/w and 40% w/w grades have different excipient compositions or processing requirements.

• Verify the meaning of the IR designation and the release characteristics of each grade.

• Follow validated pharmaceutical manufacturing and quality-control procedures.

• Do not assume that both grades are interchangeable.

• Confirm available documentation and intended application with the supplier before procurement.

13. Special Dietary / Lifestyle Tips

Dietary and lifestyle advice is relevant to patients receiving a finished itraconazole medicine, not to the pellet intermediate. Depending on the specific oral formulation, food and stomach acidity can affect absorption. Patients should follow the directions for their prescribed product and seek professional advice about potential interactions and liver-related precautions.

14. Comparison with Other Formulations

This is a general comparison. The actual formulation and performance of each product must be confirmed through its documentation and testing.

15. Precautions & Warnings

• Confirm the active ingredient, drug loading, composition, and release profile for each grade.

• Do not infer particle size, coating system, excipient content, or dissolution performance without supporting documentation.

• Assess stability and compatibility under intended manufacturing conditions.

• Ensure the finished product meets applicable quality and regulatory requirements.

• Avoid unsupported claims about manufacturing origin, certifications, or regulatory approvals.

• For clinical use, consider itraconazole’s potential for serious drug interactions, liver toxicity, and cardiac adverse effects.

16. Can I Use It With Other Medicines or Ingredients?

The pellets may be considered for combination formulations only after compatibility, stability, and performance have been evaluated. Relevant assessments may include physical compatibility, chemical stability, dissolution, and content uniformity.

Clinical co-administration of itraconazole-containing medicines with other drugs must be assessed separately by a qualified healthcare professional because itraconazole has numerous clinically significant interactions.

17. Storage

Store according to the manufacturer’s approved product specifications and technical documentation. Refer to the product packaging or applicable technical data sheet for the required storage conditions.

18. Frequently Asked Questions

Q1. What are Itraconazole IR Pellets?

They are pharmaceutical formulation intermediates containing itraconazole and intended for further processing, subject to the supplier’s specifications.

Q2. What drug loadings are available?

The supplied product description lists two drug loadings: 22.5% w/w and 40% w/w.

Q3. What does w/w mean?

W/W means weight by weight. The stated percentage represents the proportion of itraconazole by total formulation weight, subject to confirmation in the approved specification.

Q4. What does IR mean?

IR generally stands for immediate release. The actual release characteristics should be confirmed through technical documentation and appropriate testing.

Q5. Are these pellets ready for direct administration?

They should be treated as pharmaceutical intermediates for further processing, not as finished medicines for direct administration.

Q6. Is packing customizable?

Packing details are available on request and should be confirmed with the supplier.

Q7. Is a technical data sheet available?

The technical data sheet and supporting product documents can be requested from the supplier.

Q8. What is the proposed trade name?

The proposed trade name is Itracora IR. It is a suggested name only and does not imply trademark registration or regulatory approval.